Abstract :
The impact of a 2017 California law banning the use of co-payment coupons for brand-name drugs that have direct generic competitors on its first year of implementation is examined. State governments are advised to consider pairing broader coupon bans with reforms to protect patients from facing excessive cost sharing for essential medicines.